Export

ATC codes: V03AC03
EMLc
Indication
Other specified sickle cell disorders or other haemoglobinopathies ICD11 code: 3A51.Y
INN
Deferasirox
Medicine type
Chemical agent
List type
Core (EML)
(EMLc)
Formulations
Oral > Solid > dispersible tablet: 100 mg ; 125 mg ; 250 mg ; 400 mg ; 500 mg
Oral > Solid > tablet: 90 mg ; 180 mg ; 360 mg
EML status history
First added in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
deferiprone (ATC codes: V03AC02)
Patent information
Patents have expired in most jurisdictions
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended that oral deferasirox be transferred to the core list of the EML and EMLc for use in the treatment of transfusional iron overload in patients with thalassaemia syndromes, sickle cell disease and other chronic anaemias, with a square box listing specifying oral deferiprone as a therapeutic alternative. The Committee also recommended that intravenous deferoxamine should remain listed on the complementary list of the EML and EMLc for these indications, and the square box associated with the current listing be removed. The Committee accepted that the comparative efficacy and safety of deferiprone, deferoxamine and deferasirox were generally similar, and that orally administered treatments may be preferred options. The Committee recognized the value in having multiple iron chelating agents included on the Model Lists to enable countries to make appropriate national selection decisions taking into consideration relevant contextual factors.